GLP-1 weight-loss drug, whose full name is Glucagon-like peptide-1 receptor agonist. Initially, GLP-1 was a hormone secreted by the gastrointestinal tract mainly used for treating diabetes, but it has also been used to suppress appetite and control weight.
U.S. Drug Shortages Worsen to Reach a Decade High: Report
Novo Nordisk CEO to Testify Before Senate on Ozempic Pricing
Employee Benefits Survey Finds Marked Increase in GLP-1 Coverage
FDA Grants Expanded Approval for Amgen's Blincyto in ALL
Pfizer Stock Traded in the Red for Seven Straight Days
$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today
Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 9.32% on an annualized basis producing an average annual return of 20.0%. Currently, Novo Nordisk has a market capitalizat